FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT	OF CHAN	GES IN I	BENEFICIAL	OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-0287								
	Estimated average burden								
1	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Callori Fred				Ast	2. Issuer Name and Ticker or Trading Symbol Astria Therapeutics, Inc. [ATXS]							(Ch	5. Relationship of Reporting Pe (Check all applicable) X Director			10% Ow	ner	
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/02/2023							below)	(give title		Other (s _i below)	респу	
C/O ASTRIA THERAPEUTICS, INC.				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	N M	A	02109												iled by Mor		orting Persor One Repor	
(City)	(Si	tate)	Rule 10b5-1(c) Transaction Indication															
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									d to								
		Tab	e I - Nor	n-Deriv	ative \$	Sec	urities	Ac	quired, D	ispo	osed o	f, or Be	neficial	ly Owned	i			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Transaction Dispose Code (Instr. 5)		Dispose	rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		Benefici	ities For (D) (I)		rm: Direct or Indirect B (Instr. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)			
						Code	v .	Amount (A) or (D)		r Price								
		Т							uired, Dis , options					Owned			, , , , , , , , , , , , , , , , , , ,	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution I if any (Month/Day/Year) (Month/Day/Year)			Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		le and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code V (A) (D) Exercisable Date		oiration e	Amoun or Numbe of Shares										
Stock Option (Right to Buy)	\$11.35	06/02/2023			A		14,100		(1)	06/0	01/2033	Common Stock	14,100	\$0	14,100		D	

Explanation of Responses:

1. This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

/s/ Ben Harshbarger, as attorney-in-fact for Fred

06/06/2023

Callori

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.